US Drug Pricing Reform Post-Election: Scenarios To Consider And Lessons Learned

Regardless of the outcomes of the US elections, drug pricing is likely to take a back seat to COVID as policy focus. But the pandemic does offer pharma an opportunity for partnerships with payers on health outcomes. Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien and ICER’s Steve Pearson discuss where drug pricing stands in public opinion, whether policies embraced by President Trump will have staying power, and the conditions needed in the policy environment for major change.

Source: photo illustration from screenshot

Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien, ICER’s Steve Pearson and Manatt Health’s Ian Spaz discuss the prospects for Rx pricing reform during a panel of the Biopharma Congress.